Skip to main content
. 2017 Apr 5;17:97. doi: 10.1186/s12872-017-0524-3

Table 1.

Baseline and demographic data. Data are expressed as percentage (frequency) or median (IQR)

Ticagrelor (n = 142) Clopidogrel (n = 259) p
Age (years) 66 (56–73) 67 (56–67) 0.206
Age ≥ 75 years 21.8 (31) 32.0 (83) 0.037
Sex male 73.9 (105) 69.9 (81) 0.420
BMI (kg/m2)a 26 (24–30) 26 (24–29) 0.772
Hypertension 52.8 (75) 56.0 (145) 0.600
Dyslipidemia 36.6 (52) 39.0 (101) 0.668
Active smoke 45.8 (65) 37.8 (98) 0.137
Diabetes mellitus 22.5 (32) 18.5 (48) 0.362
Familiar of CAD 21.1 (30) 24.7 (64) 0.461
Previous stable angina 11.3 (16) 6.6 (17) 0.128
Previous unstable angina 3.5 (5) 4.6 (12) 0.797
Previous AMI 11.3 (16) 11.2 (29) 1.000
Previous PCI 7.0 (10) 9.3 (24) 0.574
Previous CABG 1.4 (2) 0.0 (0) 0.125
Previous CVA 4.9 (7) 7.3 (19) 0.403
PVD 16.2 (23) 11.2 (29) 0.164
Chronic kidney disease 7.0 (10) 4.6 (12) 0.361
COPD 8.5 (12) 8.9 (23) 1.000
Previous bleeding 0.7 (1) 3.9 (10) 0.106
Previous neoplasia 10.6 (15) 15.8 (41) 0.175

Italics: p value ≤0.05

BMI body mass index, CAD coronary artery disease, AMI acute myocardial infarction, PCI percutaneous coronary intervention, CABG coronary artery bypass grafting, CVA cerebrovascular accident, PVD peripheral vascular disease, COPD chronic obstructive pulmonary disease

a n = 139 for ticagrelor, 258 for clopidogrel